ASSURE Wearable ECG vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
ASSURE Wearable ECG
by Kestra Medical Technologies
VS
VX1
by Volta Medical

AI Verdict

Tool A, ASSURE Wearable ECG, focuses on continuous heart rate monitoring and remote patient data collection for at-risk cardiac patients, serving a diagnostic and monitoring role. Conversely, Tool B, VX1, is an AI software designed to assist cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures. While both are cardiology AI tools, they address different stages of patient care: remote monitoring versus intra-procedural guidance.

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you require a comprehensive, continuous, and remote monitoring solution for at-risk cardiac patients. This non-invasive wearable device provides ongoing heart rate data and automatic episode storage, enabling clinicians to remotely track patient trends and receive alerts for potential cardiac events outside of a clinical setting.

View ASSURE Wearable ECG →

Choose VX1 if…

Choose VX1 if you are an electrophysiologist seeking real-time, AI-guided assistance during atrial fibrillation or atrial tachycardia ablation procedures. This software integrates with existing EP lab systems to help identify dispersed electrograms, aiming to standardize outcomes and reduce variability during complex interventional procedures.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature ASSURE Wearable ECG VX1
Pricing Contact for pricing. Contact for pricing
Deployment Wearable device, mobile application, and cloud-based remote patient data platform. Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

Tool A emphasizes an 'intuitive' and 'mobile' experience with its wearable device and mobile application, suggesting a broader focus on user-friendliness for both patients and clinicians reviewing data remotely. While Tool B aims to streamline a complex procedure for highly trained professionals, Tool A's design appears to prioritize general ease of use for continuous monitoring.

Clinical Value

VX1

Tool B directly assists cardiac electrophysiologists in real-time during complex ablation procedures, aiming to reduce inter-operator variability and standardize outcomes, which has a direct and significant impact on treatment efficacy and patient outcomes for AFib/AT. Tool A provides valuable continuous monitoring data for early detection and trend analysis, but Tool B's impact is more immediate and direct on the success of a critical interventional treatment.

Pricing & Value

Tie

Both tools require direct contact for pricing information, indicating a lack of transparency in their pricing models. Without specific pricing details or detailed cost-benefit analyses, it is not possible to definitively determine which tool offers superior value.

Enterprise Readiness

ASSURE Wearable ECG

Tool A explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), alongside FDA clearance and a comprehensive cloud-based deployment. While Tool B is FDA-cleared and integrates with existing hospital systems, the explicit confirmation of HIPAA compliance and BAA availability is not stated in its provided facts, giving Tool A an edge in stated enterprise readiness.

Innovation

VX1

Tool B's application of AI for real-time guidance during complex cardiac ablation procedures, analyzing 3D anatomical and electrical maps to standardize outcomes, represents a significant advancement in procedural innovation. While Tool A offers innovative wearable technology and advanced signal processing for continuous monitoring, Tool B's direct, real-time AI assistance in a high-stakes interventional setting appears to be a more groundbreaking application of AI in cardiology.

Support & Docs

Tie

No information regarding support services or documentation was provided for either Tool A or Tool B in the structured facts. Without any details to compare, it is impossible to differentiate between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature ASSURE Wearable ECG VX1
Product Name ASSURE Wearable ECG VX1
Company Kestra Medical Technologies Volta Medical
Primary Function Non-therapeutic device for continuous heart rate monitoring and data collection for at-risk cardiac patients. AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Core Technology/Method Wearable ECG device with SensorFit Garment and ASSURE Detection Algorithm with Quad Channel Processingu2122 and Adaptive Patient Intelligenceu2122. AI-guided real-time identification of dispersed electrograms (EGMs) by analyzing 3D anatomical and electrical maps.
Target User/Environment At-risk cardiac patients, with data reviewed on Kestra CareStation remote patient data platform by clinicians. Cardiac electrophysiologists during AFib and atrial tachycardia ablation procedures in EP labs.
Key Feature Example Automatic episode storage and alert-based notifications. Designed to reduce inter-operator variability and standardize outcomes.

Videos

Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and VX1.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The ASSURE Wearable ECG integrates into a remote patient monitoring workflow, providing continuous heart rate data for at-risk cardiac patients outside the clinic, which clinicians can review via the Kestra CareStation remote patient data platform. In contrast, VX1 is designed for intra-procedural use, integrating with existing electrophysiology lab mapping and recording systems to offer real-time AI guidance during AFib and atrial tachycardia ablation procedures.
The ASSURE Wearable ECG utilizes the ASSURE Detection Algorithm with Quad Channel Processing and Adaptive Patient Intelligence to filter motion artifacts, enhancing the accuracy of continuous heart rate monitoring and arrhythmia detection. VX1's AI software is trained on a large database of electrograms annotated by expert electrophysiologists and offers real-time identification of dispersed electrograms during ablation, with a 'Booster mode' to increase sensitivity during AT or slow AF.
The Kestra CareStation platform for the ASSURE Wearable ECG provides clear patient reports and physiologic trend data, and Kestra states it can integrate with EHRs, HL7, and FHIR through plugins. VX1, as an intra-procedural tool, integrates with EP lab systems, and its real-time insights would typically be documented within the procedural notes in the EHR, with enhanced integration with mapping systems like Abbott's EnSite X for improved workflow.
For the ASSURE Wearable ECG, the learning curve would primarily involve familiarization with the Kestra CareStation platform for data review and alert management, with value realized through efficient remote monitoring and earlier detection of cardiac events. VX1 is designed with a simple user interface and aims to standardize outcomes across operators, suggesting a fast learning curve for electrophysiologists to integrate its real-time AI guidance into ablation procedures, potentially leading to immediate procedural benefits.
Deploying the ASSURE Wearable ECG across multiple sites would involve standardizing patient onboarding, device distribution, and remote monitoring protocols, ensuring consistent data flow to the Kestra CareStation. For VX1, multi-site rollout requires ensuring compatibility with diverse EP lab setups and training electrophysiologists across different facilities on its real-time AI guidance to standardize its use in ablation procedures and reduce inter-operator variability.
The Kestra CareStation platform for ASSURE Wearable ECG likely offers audit trails for clinician access to patient data, review of alerts, and changes in monitoring parameters, as indicated by its security features including audit logs. For VX1, audit-trail features would be important for documenting the AI's real-time identification of dispersed electrograms during ablation procedures, potentially logging when and how the AI's guidance was utilized or overridden by the physician, though specific details are not provided.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring ASSURE Wearable ECG or VX1

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

AI Tool Finder
AI-powered search. Results may not be comprehensive.